StemProtein Awarded U.S. Patent for Biodegradable Microneedle Device

by stemedica admin | Aug 22, 2021 | Company Initiatives

Dissolvable Needles Allow Dermis Delivery of Proteins and Large Molecules SAN DIEGO — August 23, 2021 — StemProtein, LLC (a subsidiary of Stemedica Cell Technologies, Inc.) a leading manufacturer of physiologically balanced growth factors, exosomes, and...

Stemedica Opens Enrollment in Phase II Clinical Trial for COVID-19 A Phase II Study in Patients with Moderate to Severe ARDS Using GMP, Allogeneic, Bone Marrow-Derived, Ischemic-Tolerant Mesenchymal Stem Cells

by stemedica admin | Aug 5, 2021 | Clinical Trials

SAN DIEGO, Aug. 5, 2021 /PRNewswire/ — Stemedica Cell Technologies, Inc. (“Stemedica”), a San Diego-based biotech company specializing in the manufacture of clinical grade stem cells, announces enrollment of patients for its...

Stemedica Signs License Agreement with Pulthera, LLC for all Respiratory Indications including those related to COVID-19

by stemedica admin | May 23, 2021 | Company Initiatives

SAN DIEGO, California, May 24, 2021 – Stemedica Cell Technologies, Inc. (“Stemedica”), a San Diego-based biotech company specializing in the manufacture of clinical grade stem cells, announced today that it has signed a Licensing Agreement with Pulthera, LLC for the...

FDA Grants IND Approval for Phase II Clinical Trial Using Stemedica’s itMSC Therapy for COVID-19 Patients

by stemedica admin | Sep 27, 2020 | Clinical Trials

SAN DIEGO, Calif. — September 28, 2020 — Stemedica Cell Technologies, Inc. has received U.S. Food and Drug Administration (FDA) Investigational New Drug (IND) approval for “A Phase II, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Assess...

Stemedica in the News! ProMedica Researchers Observe Encouraging Outcomes with Use of Allogeneic Stem Cells in COVID-19 Patients

by stemedica admin | Jul 28, 2020 | Clinical Trials

TOLEDO, Ohio, July 28, 2020 – ProMedica today announced the promising results of its new study that evaluated the use of stem cells in the treatment of adult COVID-19 patients. Eight patients elected to participate in a study under Emergency Investigational New Drug...